Cargando…
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries
PURPOSE: Health technology assessment (HTA) coverage recommendations differ across countries for the same drugs. Unlike previous studies, this study adopts a mixed methods research design to investigate, in a systematic manner, these differences. METHODS: HTA recommendations for ten orphan drugs app...
Autor principal: | Nicod, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486466/ https://www.ncbi.nlm.nih.gov/pubmed/27538758 http://dx.doi.org/10.1007/s10198-016-0823-0 |
Ejemplares similares
-
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019) -
Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014) -
How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021) -
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019) -
Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)